228 related articles for article (PubMed ID: 26937391)
1. Minimal hepatic glucose-6-phosphatase-α activity required to sustain survival and prevent hepatocellular adenoma formation in murine glycogen storage disease type Ia.
Lee YM; Kim GY; Pan CJ; Mansfield BC; Chou JY
Mol Genet Metab Rep; 2015 Jun; 3():28-32. PubMed ID: 26937391
[TBL] [Abstract][Full Text] [Related]
2. Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy.
Lee YM; Jun HS; Pan CJ; Lin SR; Wilson LH; Mansfield BC; Chou JY
Hepatology; 2012 Nov; 56(5):1719-29. PubMed ID: 22422504
[TBL] [Abstract][Full Text] [Related]
3. Glycogen storage disease type Ia mice with less than 2% of normal hepatic glucose-6-phosphatase-α activity restored are at risk of developing hepatic tumors.
Kim GY; Lee YM; Kwon JH; Cho JH; Pan CJ; Starost MF; Mansfield BC; Chou JY
Mol Genet Metab; 2017 Mar; 120(3):229-234. PubMed ID: 28096054
[TBL] [Abstract][Full Text] [Related]
4. The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia.
Lee YM; Pan CJ; Koeberl DD; Mansfield BC; Chou JY
Mol Genet Metab; 2013 Nov; 110(3):275-80. PubMed ID: 23856420
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy prevents hepatic tumor initiation in murine glycogen storage disease type Ia at the tumor-developing stage.
Cho JH; Lee YM; Starost MF; Mansfield BC; Chou JY
J Inherit Metab Dis; 2019 May; 42(3):459-469. PubMed ID: 30637773
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy using a novel G6PC-S298C variant enhances the long-term efficacy for treating glycogen storage disease type Ia.
Zhang L; Lee C; Arnaoutova I; Anduaga J; Starost MF; Mansfield BC; Chou JY
Biochem Biophys Res Commun; 2020 Jun; 527(3):824-830. PubMed ID: 32430177
[TBL] [Abstract][Full Text] [Related]
7. Recent development and gene therapy for glycogen storage disease type Ia.
Chou JY; Kim GY; Cho JH
Liver Res; 2017 Sep; 1(3):174-180. PubMed ID: 29576889
[TBL] [Abstract][Full Text] [Related]
8. Molecular biology and gene therapy for glycogen storage disease type Ib.
Chou JY; Cho JH; Kim GY; Mansfield BC
J Inherit Metab Dis; 2018 Nov; 41(6):1007-1014. PubMed ID: 29663270
[TBL] [Abstract][Full Text] [Related]
9. Type I glycogen storage diseases: disorders of the glucose-6-phosphatase/glucose-6-phosphate transporter complexes.
Chou JY; Jun HS; Mansfield BC
J Inherit Metab Dis; 2015 May; 38(3):511-9. PubMed ID: 25288127
[TBL] [Abstract][Full Text] [Related]
10. Complete normalization of hepatic G6PC deficiency in murine glycogen storage disease type Ia using gene therapy.
Yiu WH; Lee YM; Peng WT; Pan CJ; Mead PA; Mansfield BC; Chou JY
Mol Ther; 2010 Jun; 18(6):1076-84. PubMed ID: 20389290
[TBL] [Abstract][Full Text] [Related]
11. Hepatic glucose-6-phosphatase-α deficiency leads to metabolic reprogramming in glycogen storage disease type Ia.
Cho JH; Kim GY; Mansfield BC; Chou JY
Biochem Biophys Res Commun; 2018 Apr; 498(4):925-931. PubMed ID: 29545180
[TBL] [Abstract][Full Text] [Related]
12. An evolutionary approach to optimizing glucose-6-phosphatase-α enzymatic activity for gene therapy of glycogen storage disease type Ia.
Zhang L; Cho JH; Arnaoutova I; Mansfield BC; Chou JY
J Inherit Metab Dis; 2019 May; 42(3):470-479. PubMed ID: 30714174
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis of Hepatic Tumors following Gene Therapy in Murine and Canine Models of Glycogen Storage Disease.
Kang HR; Gjorgjieva M; Smith SN; Brooks ED; Chen Z; Burgess SM; Chandler RJ; Waskowicz LR; Grady KM; Li S; Mithieux G; Venditti CP; Rajas F; Koeberl DD
Mol Ther Methods Clin Dev; 2019 Dec; 15():383-391. PubMed ID: 31890731
[TBL] [Abstract][Full Text] [Related]
14. Emerging roles of autophagy in hepatic tumorigenesis and therapeutic strategies in glycogen storage disease type Ia: A review.
Cho JH; Weinstein DA; Lee YM
J Inherit Metab Dis; 2021 Jan; 44(1):118-128. PubMed ID: 32474930
[TBL] [Abstract][Full Text] [Related]
15. Liver-directed gene therapy for murine glycogen storage disease type Ib.
Kwon JH; Lee YM; Cho JH; Kim GY; Anduaga J; Starost MF; Mansfield BC; Chou JY
Hum Mol Genet; 2017 Nov; 26(22):4395-4405. PubMed ID: 28973635
[TBL] [Abstract][Full Text] [Related]
16. Mice expressing reduced levels of hepatic glucose-6-phosphatase-α activity do not develop age-related insulin resistance or obesity.
Kim GY; Lee YM; Cho JH; Pan CJ; Jun HS; Springer DA; Mansfield BC; Chou JY
Hum Mol Genet; 2015 Sep; 24(18):5115-25. PubMed ID: 26089201
[TBL] [Abstract][Full Text] [Related]
17. Glycogen storage disease type I and G6Pase-β deficiency: etiology and therapy.
Chou JY; Jun HS; Mansfield BC
Nat Rev Endocrinol; 2010 Dec; 6(12):676-88. PubMed ID: 20975743
[TBL] [Abstract][Full Text] [Related]
18. Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer.
Ghosh A; Allamarvdasht M; Pan CJ; Sun MS; Mansfield BC; Byrne BJ; Chou JY
Gene Ther; 2006 Feb; 13(4):321-9. PubMed ID: 16195703
[TBL] [Abstract][Full Text] [Related]
19. Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex.
Chou JY; Matern D; Mansfield BC; Chen YT
Curr Mol Med; 2002 Mar; 2(2):121-43. PubMed ID: 11949931
[TBL] [Abstract][Full Text] [Related]
20. The molecular basis of type 1 glycogen storage diseases.
Chou JY
Curr Mol Med; 2001 Mar; 1(1):25-44. PubMed ID: 11899241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
